Medical Devices Startups

Gatehouse Bio develops AI-powered therapeutics for pulmonary, cardiac, neurological, and autoimmune diseases by decoding small RNAs using their Code-Breaker platform to design precision medicine treatments.

1 investor

GattaCo develops a blood plasma separator device that enables point-of-care collection and transport of lab-quality plasma for remote blood testing and monitoring. The A-PON Plasma Separator uses passive elution technology to extract plasma from finger-stick blood samples for later laboratory analysis.

1 investor

Galaxy Brain Scientific develops personalized brain mapping and neuromodulation technologies for research and clinical applications across neurological conditions. The company combines proprietary platform technology for individual brain functional mapping with a non-invasive stimulation system to support precision neuroscience research.

1 investor

GBI Biomanufacturing manufactures stem cells for regenerative medicine applications, including treatments for orthopedic injuries, wound care, and arthritic conditions. The company operates a 40,000-square-foot facility in Plantation, Florida and has expanded its stem-cell production capacity to serve growing demand driven by new state legislation permitting broader clinical use of stem-cell therapies.

1 investor

GREEN VET provides diagnostic testing, health screening, and management services for companion animals, serving veterinarians and pet owners in South Korea. The company operates as a specialized animal healthcare provider offering laboratory diagnostics, digital pathology, and preventive care services.

1 investor

Gedea Biotech develops pHyph, an antibiotic-free treatment for bacterial vaginosis and other common vaginal infections aimed at supporting a healthy microbiome. A spin-out from Lund University, the company focuses on women's health and is pursuing partnerships and regulatory approvals in Europe and the US.

1 investor

GENinCode provides genomic testing for cardiovascular disease prevention and diagnosis using monogenic and polygenic risk assessment to identify patient risk and enable targeted preventive treatment. The company also offers testing for ovarian cancer surveillance, leveraging its proprietary software platform to combine genetic profiles with clinical risk factors.

1 investor

GenBody manufactures rapid diagnostic test kits, fluorescence immunoassay kits, and analysis equipment for human and veterinary use, including tests for infectious diseases, drug screening, and chronic conditions. The company also produces laboratory animals for research purposes.

1 investor

GenDx develops molecular diagnostic reagents, software, and services for transplant patient outcomes. Operating globally since 2005, the company serves the healthcare and diagnostics industry with specialized tools for transplant diagnostics.

1 investor

Gene Solutions is a biotechnology company that develops genetic testing solutions using Next-Generation Sequencing and artificial intelligence for reproductive health, clinical oncology, and multi-cancer screening. The company serves healthcare providers and patients seeking precision medicine through advanced genomic profiling and early cancer detection.

1 investor

A biotech company offering gene expression analysis tools for blood-based biomarker detection across multiple cancer types. The company develops molecular signatures and liquid biopsy solutions for biopharma, diagnostics, and CRO partners.

1 investor

Genedrive Diagnostics develops and commercialises a rapid point-of-care pharmacogenetic testing platform that detects genetic variants to guide personalised medicine decisions in emergency healthcare. The UK-based company's tests help clinicians tailor drug choices based on a patient's genetics.

1 investor

Generable develops statistical and computational models for drug development and healthcare decision-making, leveraging Bayesian methods and probabilistic modeling. The company serves pharmaceutical and biotech organizations in developing safer and more efficient therapeutic interventions.

1 investor

General Inception is an operational support and company building firm that handles day-to-day planning and execution for building companies, with a focus on life science tools and diagnostics.

1 investor

Adapsyn Bioscience is a biotechnology company that uses proprietary algorithms and artificial intelligence to analyze genomic and metabolomic data from microbes in order to discover novel small molecule natural product drug candidates.

1 investor

GeneTech provides non-invasive prenatal testing (NIPT) using fetal cell-free DNA from maternal blood, along with clinical laboratory testing services, offered to certified medical institutions in Japan. It introduced NIPT in Japan in 2013 and runs a domestic analysis lab, serving pregnant patients and their families through partner hospitals.

1 investor

Geneticure offers a patented genetic test that uses a cheek-swab DNA sample, analyzing 17 genotypes across 11 genes to recommend personalized hypertension (blood pressure) treatment plans. The test helps doctors prescribe effective treatments by assessing the responsiveness of the patient's cardiac, vascular, and renal systems, reducing trial-and-error prescribing.

1 investor

GENEWIZ provides sequencing, synthesis, and molecular biology services for research, clinical, and therapeutic applications, serving academic institutions, biotech companies, and pharmaceutical organizations.

1 investor

GeniPhys develops Collymer, a patented polymerizable (scaffold-forming) collagen technology used to design and fabricate collagen biomaterials for tissue restoration and regeneration. Its materials target regenerative medicine applications including soft tissue, cardiovascular, musculoskeletal, and orthopedic replacements, as well as delivery of pharmaceutical and cell-based therapies and device coatings.

1 investor

Genomadix develops the Cube, a point-of-care PCR platform for real-time molecular testing in precision medicine and environmental applications. The company commercializes FDA-cleared genotyping tests and offers its open platform for partnerships with assay developers and clinical laboratories.

1 investor

Genome Medical provides telehealth-enabled genetic counseling, testing, and clinical trial access for patients with rare diseases. The company partners with hospitals, health systems, and life sciences organizations to deliver expert genetic services at scale.

1 investor

GenoME develops liquid biopsy tests using DNA methylation biomarkers for early disease detection and monitoring, particularly in cancer diagnostics. The company's pipeline identifies novel biomarkers and delivers rapid, cost-effective PCR tests for applications including companion diagnostics and disease monitoring.

1 investor

Omzey (formerly GenomeUp) develops JuliaOmix, a diagnostic suite designed to accelerate the diagnosis of rare diseases using omics sciences. The company serves clinicians, researchers, and patients working in rare disease diagnostics and precision medicine.

1 investor

Genomic Vision is a genome analysis company whose Molecular Combing technology characterizes DNA at single-molecule resolution for quality control in bioproduction and cell and gene therapy, as well as for drug discovery research. It serves pharmaceutical, biotech, and research organizations developing gene therapies and studying DNA replication.

1 investor